Several mechanisms have been attributed to the insufficient clinical benefit of FLT3 inhibitors including pharmacokinetic challenges and treatment-induced point mutations in the FLT3 gene that render AML cells resistant to the FLT3 kinase inhibitors [53, 54]. This evidence concerns the gene FLT3 and acute myeloid leukemia.